Stock AXSM AXSOME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
72.5 USD -1.60% Intraday chart for Axsome Therapeutics, Inc. -3.07% -8.91%
May. 08 Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating MT
May. 07 Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating
MT
Axsome Therapeutics to Present at Upcoming Investor Conferences
GL
Axsome Therapeutics to Present at Upcoming Investor Conferences
AQ
Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating
MT
Transcript : Axsome Therapeutics, Inc., Q1 2024 Earnings Call, May 06, 2024
Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell
MT
Axsome: Q1 Earnings Snapshot
AQ
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M
MT
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Axsome Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return
DJ
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
GL
North American Morning Briefing : More Earnings -2-
DJ
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says
MT
Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90
MT
Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting
AQ
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
GL
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AQ
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
GL
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXSM Stock
  4. News Axsome Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW